reported that tumor infiltrating Tregs can express surface specific molecules such as PD-L1 and PD-L2 in order to bind their receptors on the surface of CD8+ T cells, inhibiting CD8+ T-cell activation, which also supported our outcomes and hypothesis (36). The gene discussed is CD8A; the disease is neoplasm.